The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Adjuvant chest wall irradiation should be omitted in most patients meeting the eligibility criteria for SUPREMO,” said Ian Kunkler, MB BChir.

(RTTNews) - OS Therapies, Inc. (OSTX) Wednesday announced that it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology programs and related ...

Pathologists supported by a new artificial intelligence tool outperformed Standard of Care/Gold standard in determining ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...

A new study led by researchers at Moffitt Cancer Center shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed.